The section as a whole has attracted over 115,000 page views; the top five most read articles are: Cough is the most common symptom for which people seek medical advice, and patients with cough frequently present to community pharmacy.
However, many of the therapies available over the counter are currently recommended based on custom and traditional practice, which is not supported by clinical studies of sufficient quality to meet the standards of modern evidence-based medicine.
Although a number of locally isolated examples of good practice in UK emergency departments and urgent care settings exist, there is little published evidence to support the role of pharmacists practising clinically in these settings.
As a result of the lack of evidence nationally and internationally regarding pharmacists clinically managing patients, HEE West Midlands and its national partners began a three-year research programme in 2013.
Authored by Sharanie Sims, Elizabeth Neuner and Robert Bonomo (Cleveland Veterans Affairs Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, United States), this article describes the mechanism of action and resistance, spectrum of activity, pharmacokinetics and dynamics, as well as the clinical efficacy and safety data for ceftazidime-avibactam.
The top articles from 2017 cover a range of clinical topics, with contributions from globally renowned key opinion leaders, which highlight the global focus and reach of the journal.
This article by Matthew Aiello (Health Education England) describes this pilot in more detail and outlines how these programmes contribute to the understanding and adoption of pharmacist advanced clinical training, with reference to Health Education England’s plan for pharmacists and their future roles.
Do you agree that enhanced clinical development pathways for pharmacists should be developed?
Developing new antimicrobial agents is one of the seven key areas for action in the UK five-year antimicrobial resistance strategy.
The last article rounding-off our top five provides a general overview of the current published data on ceftazidime-avibactam, a new cephalosporin and β-lactamase inhibitor combination antibiotic, which received marketing authorisation by the European Medicines Agency in April 2016.